RxDoctor Payments Data

Cameron Siddens, MD

Endocrinology, Diabetes & Metabolism · Colorado Springs, CONPI 1356787436

Payments from drug & device makers

$917in general payments, 2019–2025

Across 16 payments — averaging $57.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Tandem Diabetes Care, Inc.$421
  • Insulet Corporation$150
  • Amgen$106
  • Amphastar Pharmaceuticals, Inc.$74
  • Dexcom, Inc.$70
  • Abbott$60
  • plus $36 from 2 others

What the payments were for

  • Speaking & faculty fees$30033%
  • Food & beverage$55761%
  • Education$607%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$917 in reported general payments places this provider in the 40th percentile of 120 endocrinology, diabetes & metabolism providers in Colorado.

See all endocrinology, diabetes & metabolism providers in Colorado

Medicare billing

Part B allowed, 2024
$452,255
Medicare patients
619
Services billed
25,906

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
ForteoTeriparatide28$127,158
TrulicityDulaglutide79$119,691
OzempicSemaglutide63$82,783
Humulin R U-500 KwikpenInsulin Regular, Human36$80,160
Somatuline DepotLanreotide Acetate12$75,065
MounjaroTirzepatide46$72,596
Tresiba Flextouch U-200Insulin Degludec18$46,086
Teriparatide17$43,072
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog20$26,091
JardianceEmpagliflozin17$24,536
Humalog Kwikpen U-200Insulin Lispro12$24,439
Tresiba Flextouch U-100Insulin Degludec22$21,183
FarxigaDapagliflozin Propanediol11$17,923
Novolog FlexpenInsulin Aspart39$11,918
Humalog Kwikpen U-100Insulin Lispro27$10,222

Paid to pharmacies, not to this prescriber.

Other endocrinology, diabetes & metabolism in Colorado Springs

See the full list for Colorado

Where these figures come from

Is this you, or does something look wrong? →